Cost-effectiveness of alternative outpatient pelvic inflammatory disease treatment strategies

Sexually Transmitted Diseases

Volumn 34, Issue 12, 2007, Pages 960-966

  Smith, Kenneth J ^a,c   Ness, Roberta B ^b   Wiesenfeld, Harold C ^a   Roberts, Mark S ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFOXITIN; CEFTRIAXONE; DOXYCYCLINE; LEVOFLOXACIN; METRONIDAZOLE; OFLOXACIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HUMAN; INFECTION RISK; MEDICAL RESEARCH; OUTPATIENT CARE; PELVIC INFLAMMATORY DISEASE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RISK REDUCTION; STATISTICAL MODEL; TREATMENT DURATION;

AMBULATORY CARE; ANTI-BACTERIAL AGENTS; COST-BENEFIT ANALYSIS; DOXYCYCLINE; DRUG THERAPY, COMBINATION; ERYTHROMYCIN; FEMALE; HUMANS; MARKOV CHAINS; METRONIDAZOLE; OFLOXACIN; PELVIC INFLAMMATORY DISEASE;

EID: 36348979303     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e3181161d47     Document Type: Article

References (41)

1. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2006. MMWR Morb Mortal Wkly Rep 2006; 55 (RR11):1-94.
2. Berger GS, Westrom L. Pelvic Inflammatory Disease. New York: Raven Press, 1992.
3. Beigi RH, Wiesenfeld HC. Pelvic inflammatory disease: New diagnostic criteria and treatment. Obstet Gynecol North Am 2003; 30:777-793.
4. Sutton MY, Sternberg M, Zaidi A, et al. Trends in pelvic inflammatory disease hospital discharges and ambulatory visits, United States, 1985-2001. Sex Transm Dis 2005; 32:778-784.
5. Rein DB, Kassler WJ, Irwin KL, et al. Direct medical cost of pelvic inflammatory disease and its sequelae: Decreasing, but still substantial. Obstet Gynecol 2000; 95:397-402.
6. Drug Topics Red Book. Montvale, NJ: Medical Economics, 2004.
7. Gold MR, Siegel JE, Russell LB, et al, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
8. US Department of Labor, Bureau of Labor Statistics website. Consumer price index. Available at www.bls.gov/data/. Accessed September 27, 2006.
9. Haggerty CL, Ness RB. Epidemiology, pathogenesis and treatment of pelvic inflammatory disease. Expert Rev Anti Infect Ther 2006;4:235-247.
10. Arias E. United States life tables, 2002. National Vital Statistics Reports. Vol 53, No. 6. Hyattsville, Maryland: National Center for Health Statistics, 2004.
11. Ness RB, Trautmann G, Richter HE, et al. Effectiveness of treatment strategies of some women with pelvic inflammatory disease: A randomized trial. Obstet Gynecol 2005; 106:573-580.
12. Ness RB, Soper DE, Holley RL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: Results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) randomized trial. Am J Obstet Gynecol 2002; 186:929-937.
13. Yeh JM, Hook EW III, Goldie SJ. A refined estimate of the average lifetime cost of pelvic inflammatory disease. Sex Transm Dis 2003;30:369-378.
14. Van Den Eeden SK, Shan J, Bruce C, et al. Ectopic pregnancy rate and treatment utilization in a large managed care organization. Obstet Gynecol 2005; 105:1052-1057.
15. Washington AE, Katz P. Cost of and payment source for pelvic inflammatory disease. Trends and projections, 1983 through 2000. JAMA 1991; 266:2565-2569.
16. Joesoef MR, Westrom L, Reynolds G, et al. Recurrence of ectopic pregnancy: The role of salpingitis. Am J Obstet Gynecol 1991; 165:46-50.
17. Washington AE, Arno PS, Brooks MA. The economic cost of pelvic inflammatory disease. JAMA 1986; 255:1735-1738.
18. Wiesenfeld HC, Sweet RL. Progress in the management of tuboovarian abscesses. Clin Obstet Gynecol 1993; 36:433-444.
19. Landers DV, Sweet RL. Tubo-ovarian abscess: Contemporary approach to management. Rev Infect Dis 1983; 5:876-884.
20. Dunbar-Jacob J, Sereika SM, Foley SM, et al. Adherence to oral therapies in pelvic inflammatory disease. J Women's Health 2004; 13:285-291.
21. Schwebke JR, Sadler R, Sutton JM, et al. Positive screening tests for gonorrhea and chlamydial infection fail to lead consistently to treatment of patients attending a sexually transmitted disease clinic. Sex Transm Dis 1997; 24:181-184.
22. Hu D, Hook EW III, Goldie SJ. Screening for Chlamydia trachomatis in women 15 to 29 years of age: A cost-effectiveness analysis. Ann Intern Med 2004; 141:501-513.
23. Westrom L, Joesoef R, Reynolds G, et al. Pelvic inflammatory disease and fertility. A cohort study of 1844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex Transm Dis 1992; 19:185-192.
24. Carey JC, Klebanoff MA, Hauth JC, et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. N Engl J Med 2000; 342:534-540.
25. McGregor JA, Crombleholme WR, Newton E, et al. Randomized comparison of ampicillin-sulbactam to cefoxitin and doxycycline or clindamycin and gentamicin in the treatment of pelvic inflammatory disease or endometritis. Obstet Gynecol 1994; 83:998-1004.
26. Wolner-Hanssen P, Paavonen J, Kiviat N, et al. Ambulatory treatment of suspected pelvic inflammatory disease with augmentin, with or without doxycycline. Am J Obstet Gynecol 1988; 158:577-579.
27. Flagyl (metronidazole) Package Insert. Available at www.pfizer.com/ pfizer/download/uspi_flagyl.pdf. Accessed September 27, 2006.
28. Magid D, Douglas JM Jr, Schwartz JS. Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: An incremental cost-effectiveness analysis. Ann Intern Med 1996; 124:389-399.
29. Chlamydia. In: Stratton KR, Durch J, Lawrence RS, eds. Vaccines for the 21st Century: A Tool for Decision Making. Washington, DC: National Academy Press, 2000. Pp. 149-158.
30. Westrom L, Eschenbach D. Pelvic inflammatory disease. In: Holmes KK, ed. Sexually Transmitted Diseases, 3rd ed. New York: McGraw-Hill, Health Professions Division, 1999.
31. Koerkamp BG, Myriam Hunink MG, Stijnen T, et al. Identifying key parameters in cost-effectiveness analysis using value of information: A comparison of methods. Health Econ 2006; 15:383-392.
32. Claxton KP, Sculpher MJ. Using value of information analysis to prioritise health research: Some lessons from recent UK experience. Pharmacoeconomics 2006; 24:1055-1068.
33. Sculpher M, Claxton K. Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty - When is there sufficient evidence? Value Health 2005; 8:433-446.
34. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146:473-481.
35. Tappenden P, Chilcott JB, Eggington S, et al. Methods for expected value of information analysis in complex health economic models: Developments on the health economics of interferon-beta and glatiramer acetate for multiple sclerosis. Health Technol Assess. 2004; 8:iii, 1-78.
36. Martens MG, Gordon S, Yarborough DR, et al. Multicenter randomized trial of ofloxacin versus cefoxitin and doxycycline in outpatient treatment of pelvic inflammatory disease. Ambulatory PID Research Group. South Med J 1993; 86:604-610.
37. Peipert JF, Sweet RL, Walker CK, et al. Evaluation of ofloxacin in the treatment of laparoscopically documented acute pelvic inflammatory disease (salpingitis). Infect Dis Obstet Gynecol 1999; 7:138-144.
38. Walker CK, Workowski KA, Washington AE, et al. Anaerobes in pelvic inflammatory disease: implications for the Centers for Disease Control and Prevention's guidelines for treatment of sexually transmitted diseases. Clin Infect Dis 1999; 28(suppl 1):S29 -S36.
39. Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150:1881-1884.
40. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487-497.
41. Bevan CD, Ridgway GL, Rothermel CD. Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. J Int Med Res 2003; 31:45-54.